Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Akebia Therapeutics Inc.

    NASDAQ: AKBA · Real-Time Price · USD
    3.67
    0.03 (0.82%)
    At close: Jun 24, 2025, 3:59 PM
    3.72
    1.22%
    Pre-market: Jun 25, 2025, 07:00 AM EDT

    Akebia Therapeutics Statistics

    Share Statistics

    Akebia Therapeutics has 262.64M shares outstanding. The number of shares has increased by 24.64% in one year.

    Shares Outstanding

    n/a
    		 262.64M

    Shares Change (YoY)

    n/a
    		 24.64%

    Shares Change (QoQ)

    n/a
    		 19.73%

    Owned by Institutions (%)

    n/a
    		 32.25%

    Shares Floating

    n/a
    		 251.57M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,425

    FTD / Avg. Volume

    n/a
    		 0.03%

    Short Selling Information

    The latest short interest is 20.05M, so 7.64% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 20.05M

    Short % of Shares Out

    n/a
    		 7.64%

    Short % of Float

    n/a
    		 7.72%

    Short Ratio (days to cover)

    n/a
    		 3.9

    Valuation Ratios

    The PE ratio is -5.77 and the forward PE ratio is 51.86. Akebia Therapeutics's PEG ratio is -0.32.

    PE Ratio

    n/a
    		 -5.77

    Forward PE

    n/a
    		 51.86

    PS Ratio

    n/a
    		 2.5

    Forward PS

    n/a
    		 1.9

    PB Ratio

    n/a
    		 -8.15

    P/FCF Ratio

    n/a
    		 -9.85

    PEG Ratio

    n/a
    		 -0.32
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Akebia Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.41, with a Debt / Equity ratio of -0.97.

    Current Ratio

    n/a
    		 1.41

    Quick Ratio

    n/a
    		 1.21

    Debt / Equity

    n/a
    		 -0.97

    Debt / EBITDA

    n/a
    		 -3.47

    Debt / FCF

    n/a
    		 -1.17

    Interest Coverage

    n/a
    		 -2.78

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $884,972.38

    Profits Per Employee

    n/a
    		 $-383,480.66

    Employee Count

    n/a
    		 181

    Asset Turnover

    n/a
    		 0.73

    Inventory Turnover

    n/a
    		 3.89

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 328.39% in the last 52 weeks. The beta is 0.84, so Akebia Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.84

    52-Week Price Change

    n/a
    		 328.39%

    50-Day Moving Average

    n/a
    		 2.83

    200-Day Moving Average

    n/a
    		 2.07

    Relative Strength Index (RSI)

    n/a
    		 63.53

    Average Volume (20 Days)

    n/a
    		 5,020,037

    Income Statement

    In the last 12 months, Akebia Therapeutics had revenue of 160.18M and earned -69.41M in profits. Earnings per share was -0.33.

    Revenue

    n/a
    		 160.18M

    Gross Profit

    n/a
    		 97M

    Operating Income

    n/a
    		 -50.47M

    Net Income

    n/a
    		 -69.41M

    EBITDA

    n/a
    		 -13.72M

    EBIT

    n/a
    		 -51.23M

    Earnings Per Share (EPS)

    n/a
    		 -0.33
    Full Income Statement

    Balance Sheet

    The company has 51.87M in cash and 47.64M in debt, giving a net cash position of 4.23M.

    Cash & Cash Equivalents

    n/a
    		 51.87M

    Total Debt

    n/a
    		 47.64M

    Net Cash

    n/a
    		 4.23M

    Retained Earnings

    n/a
    		 -1.68B

    Total Assets

    n/a
    		 310.19M

    Working Capital

    n/a
    		 112.56M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -40.66M and capital expenditures -33K, giving a free cash flow of -40.69M.

    Operating Cash Flow

    n/a
    		 -40.66M

    Capital Expenditures

    n/a
    		 -33K

    Free Cash Flow

    n/a
    		 -40.69M

    FCF Per Share

    n/a
    		 -0.19
    Full Cash Flow Statement

    Margins

    Gross margin is 60.56%, with operating and profit margins of -31.51% and -43.33%.

    Gross Margin

    n/a
    		 60.56%

    Operating Margin

    n/a
    		 -31.51%

    Pretax Margin

    n/a
    		 -43.33%

    Profit Margin

    n/a
    		 -43.33%

    EBITDA Margin

    n/a
    		 -8.57%

    EBIT Margin

    n/a
    		 -31.51%

    FCF Margin

    n/a
    		 -25.4%

    Dividends & Yields

    AKBA does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for AKBA is $6.5, which is 77.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $6.5

    Price Target Difference

    n/a
    		 77.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -5.16

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist